| P50 | author | Peter Palese | Q1795041 |
| | James Duehr | Q37367031 |
| | Viviana Simon | Q54435264 |
| | Matthew J. Evans | Q55303072 |
| | Victor H Leyva-Grado | Q56812339 |
| | Mark J. Bailey | Q57134671 |
| | Julia A Brown | Q89453034 |
| | Jean K Lim | Q92004874 |
| | Maria Carolina Bermúdez-González | Q92815067 |
| | Felix Broecker | Q101244378 |
| | Fortuna O Arumemi | Q114778833 |
| | Florian Krammer | Q41531975 |
| | Gene S. Tan | Q47502916 |
| P2093 | author name string | Rong Hai | |
| | Harrison Dulin | |
| P2860 | cites work | Zika Virus Associated with Microcephaly | Q22683189 |
| | Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study | Q23012849 |
| | Association between Zika virus and microcephaly in French Polynesia, 2013–15: a retrospective study | Q24255260 |
| | Transmission of Zika Virus Through Sexual Contact with Travelers to Areas of Ongoing Transmission — Continental United States, 2016 | Q24261160 |
| | Possible Association Between Zika Virus Infection and Microcephaly — Brazil, 2015 | Q24261167 |
| | Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo | Q24568302 |
| | Flavivirus NS1: a multifaceted enigmatic viral protein | Q26247192 |
| | Broadly Neutralizing Activity of Zika Virus-Immune Sera Identifies a Single Viral Serotype | Q26252060 |
| | Specificity, cross-reactivity and function of antibodies elicited by Zika virus infection | Q26252507 |
| | Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment | Q26746185 |
| | Antibodies against West Nile Virus Nonstructural Protein NS1 Prevent Lethal Infection through Fc Receptor-Dependent and -Independent Mechanisms | Q27472823 |
| | Antibody Recognition of Cell Surface-Associated NS1 Triggers Fc- Receptor-Mediated Phagocytosis and Clearance of West Nile Virus-Infected Cells | Q27481025 |
| | Secreted NS1 of Dengue Virus Attaches to the Surface of Cells via Interactions with Heparan Sulfate and Chondroitin Sulfate E | Q27481677 |
| | Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1 | Q27486827 |
| | Virus-Specific Cytolytic Antibodies to Nonstructural Protein 1 of Japanese Encephalitis Virus Effect Reduction of Virus Output from Infected Cells | Q27488397 |
| | Highly Conserved Protective Epitopes on Influenza B Viruses | Q27671404 |
| | An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations | Q27685255 |
| | Zika Virus Infection as a Cause of Congenital Brain Abnormalities and Guillain–Barré Syndrome: Systematic Review | Q28114477 |
| | Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus Species | Q28119651 |
| | A novel Zika virus mouse model reveals strain specific differences in virus pathogenesis and host inflammatory immune responses | Q28954560 |
| | Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity | Q29196526 |
| | Prospects for a dengue virus vaccine | Q29619608 |
| | Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico | Q30145646 |
| | Prospects for a Zika Virus Vaccine | Q30235612 |
| | Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1. | Q33414156 |
| | Control of acute dengue virus infection by natural killer cells | Q33633893 |
| | Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1 | Q33870167 |
| | Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen | Q34953172 |
| | Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection | Q36515143 |
| | Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection | Q36991414 |
| | Antibody-based assay discriminates Zika virus infection from other flaviviruses | Q38157718 |
| | Delayed and highly specific antibody response to nonstructural protein 1 (NS1) revealed during natural human ZIKV infection by NS1-based capture ELISA. | Q55084361 |
| | Incorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E protein | Q56000963 |
| | Zika Virus | Q56427410 |
| | Protective and immunological behavior of chimeric yellow fever dengue vaccine | Q38731663 |
| | Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions | Q38748910 |
| | Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus | Q38782718 |
| | Reduction of yellow fever virus mouse neurovirulence by immunization with a bacterially synthesized non-structural protein (NS1) fragment | Q38930859 |
| | Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice | Q40052932 |
| | Structural Basis of Zika Virus-Specific Antibody Protection | Q40056291 |
| | Antibodies against nonstructural protein 1 protect mice from dengue virus-induced mast cell activation | Q40067512 |
| | Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination | Q40140017 |
| | Protection against dengue type 2 virus induced in mice immunized with a DNA plasmid encoding the non-structural 1 (NS1) gene fused to the tissue plasminogen activator signal sequence | Q40500253 |
| | The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice | Q40722416 |
| | Passive protection studies in mice with monoclonal antibodies directed against the non-structural protein NS3 of dengue 1 virus | Q40764696 |
| | Synergistic Interactions of Anti-NS1 Monoclonal Antibodies Protect Passively Immunized Mice from Lethal Challenge with Dengue 2 Virus | Q40784132 |
| | Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus non-structural glycoprotein NS1. | Q40798835 |
| | Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48. | Q40814867 |
| | Distinguishing secondary dengue virus infection from Zika virus infection with previous dengue by a combination of three simple serological tests | Q41918088 |
| | Rapid antigen tests for dengue virus serotypes and Zika virus in patient serum. | Q41918245 |
| | Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice | Q41919718 |
| | A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model | Q43046676 |
| | Refined protocol for generating monoclonal antibodies from single human and murine B cells | Q43141303 |
| | Humoral Immune Responses Against Zika Virus Infection and the Importance of Preexisting Flavivirus Immunity | Q47558315 |
| | Tick-Borne Encephalitis Virus Vaccine-Induced Human Antibodies Mediate Negligible Enhancement of Zika Virus Infection InVitro and in a Mouse Model | Q50052067 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Zika virus | Q202864 |
| | general chemistry | Q909510 |
| P5008 | on focus list of Wikimedia project | WikiProject Zika Corpus | Q54439832 |
| P304 | page(s) | 4560 | |
| P577 | publication date | 2018-11-01 | |
| P1433 | published in | Nature Communications | Q573880 |
| P1476 | title | Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model | |
| P478 | volume | 9 | |